Market Overview

UPDATE: Bank of America Initiates Intercept Pharmaceuticals at Buy on Regulatory Outlook

Share:
Related ICPT
Genfit's Loss Is Gain For Intercept Pharmaceuticals
Why Intercept Might Be A Better Bet Than Biogen Right Now
Biotech Beat: 3/26/15 - Intercept Pharmaceuticals (Seeking Alpha)

Bank of America initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Buy rating and a $29 price objective.

Bank of America noted, "We are initiating coverage of Intercept pharmaceuticals (ICPT) with a Buy rating and DCF derived $29 PO. ICPT is a development stage pharmaceutical company focused on bile acid derived therapeutics. The company's lead product is OCA, a bile acid derivative, for the treatment of a rare autoimmune liver disease, primary billiary cirrhosis (PBC). We expect OCA will report positive Phase 3 trial results (2014). Our PO incorporates a heavier than normal risk adjustment for US approval pending additional clarity on the regulatory pathway in 2013; success in additional indications (e.g. portal hypertension) represent upside to our PO."

Intercept Pharmaceuticals closed at $20.00 on Friday.

Latest Ratings for ICPT

DateFirmActionFromTo
Mar 2015Janney CapitalMaintainsBuyBuy
Mar 2015Leerink SwannMaintainsMarket Perform
Mar 2015BairdMaintainsOutperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ICPT)

Around the Web, We're Loving...